Lymphocyte Immunoglobulin Secretion during Short-term Treatment with Cephalosporins in Vivo and in Vitro: Effects on Plaque-forming Cell Response of Human Peripheral Blood Lymphocytes

1986 ◽  
Vol 18 (1) ◽  
pp. 83-84
Author(s):  
Palle Tauris ◽  
Finn T. Black
Keyword(s):  
Cell Response ◽  
Human Peripheral Blood ◽  
Peripheral Blood Lymphocytes ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Human Peripheral Blood Lymphocytes ◽  
In Vitro Effects

In vitro effects of methadone on lymphocyte proliferation following a short-term treatment with methotrexate-loaded liposomes in a murine model of arthritis

2006 ◽  
Vol 164 ◽  
pp. S110-S111
Author(s):  
Maria Barca ◽  
Anne Marie Ciobanu ◽  
Dan Balalau ◽  
Daniela Luiza Baconi ◽  
Mihaela Ilie ◽  
...  
Keyword(s):  
Murine Model ◽  
Lymphocyte Proliferation ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
In Vitro Effects

scholarly journals Evaluation of cytotoxicity and mutagenicity of the benzodiazepine flunitrazepam in vitro and in vivo

2014 ◽  
Vol 50 (2) ◽  
pp. 251-256
Author(s):  
Igor Vivian de Almeida ◽  
Giovana Domingues ◽  
Lilian Capelari Soares ◽  
Elisângela Düsman ◽  
Veronica Elisa Pimenta Vicentini
Keyword(s):  
Rattus Norvegicus ◽  
Bone Marrow Cells ◽  
Micronucleus Test ◽  
Term Treatment ◽  
Genotoxic Effects ◽  
Short Term ◽  
Short Term Treatment ◽  
Chromosomal Aberration Test

Flunitrazepam (FNZ) is a sedative benzodiazepine prescribed for the short-term treatment of insomnia. However, there are concerns regarding possible carcinogenic or genotoxic effects of this medicine. Thus, the aim of this study was to evaluate the cytotoxic, clastogenic and aneugenic effects of FNZ in hepatoma cells from Rattus norvegicus (HTC) in vitro and in bone marrow cells of Wistar rats in vivo. These effects were examined in vitro following treatment with 0.2, 1.0, 5.0 or 10 μg/mL FNZ using a micronucleus test with a cytokinesis block or in vivo using a chromosomal aberration test following treatment with 7, 15 or 30 μg/mL/kg body weight. The results showed that the benzodiazepine concentrations tested were not cytotoxic, aneugenic or clastogenic. However, considering the adverse effects of using this benzodiazepine, more studies are required.

scholarly journals Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model

2007 ◽  
Vol 56 (8) ◽  
pp. 1047-1051 ◽  
Author(s):  
Sean T. Byrne ◽  
Steven M. Denkin ◽  
Peihua Gu ◽  
Eric Nuermberger ◽  
Ying Zhang
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Term Treatment ◽  
New Drugs ◽  
Bacteriostatic Effect ◽  
Short Term ◽  
Short Term Treatment ◽  
Neutral Conditions

There is an urgent need for the development of new drugs that are active against drug-resistant Mycobacterium tuberculosis strains and can shorten tuberculosis (TB) therapy. It has previously been reported that the azole class of antifungals has anti-TB activity in vitro. This study evaluated ketoconazole (KTC) for activity against M. tuberculosis. The MIC of KTC for different M. tuberculosis strains ranged from 8 to 16 μg ml−1 under both acidic and neutral conditions, with the minimum bactericidal concentration being about twofold higher than the MIC. KTC had enhanced activity against old, non-growing bacilli in vitro when combined with pyrazinamide (PZA) and rifampicin (RIF). A single oral dose of KTC at 75 mg kg−1 led to an inhibitory serum concentration 2 h after administration. The in vivo activity of KTC was evaluated in established pulmonary TB in the murine model, compared alone and in combination with isoniazid (INH), PZA and RIF. KTC alone exhibited little effect after short-term treatment, with a borderline bacteriostatic effect on spleen colony counts but not on lung counts. KTC, when added in combination with INH, PZA and RIF, significantly improved the treatment outcome in the lungs (compared with treatment with INH, PZA and RIF). The lowest numbers of bacilli in lungs were found in mice treated with KTC, PZA and RIF. Further investigation is necessary to determine the role of KTC in the treatment of TB.

scholarly journals Nivalenol induced apoptosis in human peripheral blood lymphocytes in vitro and mouse peripheral blood lymphocytes in vivo

1997 ◽  
Vol 1997 (45) ◽  
pp. 33-37 ◽  
Author(s):  
Naoto YOSHINO ◽  
Mari TAKIZAWA ◽  
Hiroki OKUMURA ◽  
Tomomi IHARA ◽  
Masao SUGAMATA ◽  
...  
Keyword(s):  
Peripheral Blood ◽  
Human Peripheral Blood ◽  
Peripheral Blood Lymphocytes ◽  
Blood Lymphocytes ◽  
Human Peripheral Blood Lymphocytes ◽  
Induced Apoptosis

scholarly journals Short-term treatment with mycophenolic acid and tacrolimus is tolerogenic for INS-1 cell clone transplantation and the deleterious effects of the drugs are limited: in vivo and in vitro studies

2005 ◽  
Vol 186 (1) ◽  
pp. 213-220
Author(s):  
M Asfari ◽  
S Berta ◽  
S Coffy ◽  
M Kergoat ◽  
C Charon ◽  
...  
Keyword(s):  
Mycophenolic Acid ◽  
Cell Clone ◽  
Day Treatment ◽  
Immunosuppressive Drugs ◽  
Term Treatment ◽  
Β Cell ◽  
Short Term ◽  
Short Term Treatment

One of the major requirements for a successful and life-lasting organ transplant is the access to safe, least toxic and permanent tolerance-inducing drugs. In this study we wished to evaluate the effects of tolerogenic doses of the immunosuppressive drugs mycophenolic acid (MPA) and tacrolimus (Tac) on clonal β-cell lines, both in vivo and in vitro. Here we demonstrate that combined administration of low-dose MPA and Tac for 23 days induced permanent tolerance in an allogeneic β-cell line transplant in Wistar rat liver through the portal vein. This short-term treatment of tolerogenic doses of the two drugs was deleterious to the survival of the transplanted cells but a small percentage of the cells could resist the effect and become fully active when the drugs were removed. The surviving cells, retrieved from growth in vivo, did not exhibit increased resistance in comparison to the original cells when tested in vitro at two glucose concentrations, 10 and 20 mM. The presence of a small percentage of resistant cells at the two glucose concentrations was also detected in the in vitro study after a continuous 8-day treatment demonstrating that the in vivo resistance was not related to micro-environmental protection but possibly to a phenotypic cell state that is yet to be determined.

DER TSH-RESERVE-TEST AN DER RATTE

1963 ◽  
Vol 44 (4) ◽  
pp. 570-580 ◽  
Author(s):  
H. W. Iff ◽  
H. Studer ◽  
F. Wyss
Keyword(s):  
Time Course ◽  
Term Treatment ◽  
Short Term ◽  
Iodide Uptake ◽  
Short Term Treatment ◽  
Similar Time ◽  
Clinical Method ◽  
Tsh Secretion

ABSTRACT A rebound of 131I-uptake by the thyroid gland after a thyrostatic treatment may be taken as evidence of an unimpaired pituitary TSH-secretion. The iodide uptake in vivo and the iodide accumulation in vitro were studied in rat thyroids following a short-term treatment of the animals with carbimazole. The experiments served as models for the clinical method of assaying the pituitary TSH-reserve. The total iodide uptake reaches a peak 36 hours after the end of a carbimazole treatment and returns to normal after 96 hours. The rebound of the iodide accumulation has a similar time course. Extending the carbimazole treatment from 6 to 12 days leads to a definite increase in the peak iodide accumulation while the peak of the total iodide uptake was not significantly increased. The duration of the rebound-phase is not changed by prolonged carbimazole treatment.

Sign in / Sign up

Export Citation Format

Share Document